SAN ANTONIO, TX, Dec. 1, 2020 /PRNewswire/ —
The 43rd Virtual San Antonio Breast Cancer Symposium (SABCS®) is just one week away!
Register now to the Official Best of SABCS® News 2020 program to get a daily update on the most relevant advances in breast cancer.
Encore Medical Education (www.encoremeded.com) will publish a new edition of the Official Best of SABCS® News from the 2020 San Antonio Breast Cancer Symposium (SABCS®) starting December 9, 2020.
Registration is now open to access the Official Best of SABCS® News. Registration is open to health care professionals at no fee at www.bestofsabcsnews.com . The first video news from the most relevant abstracts will be published starting December 9, 2020 at 4:00 pm CDT (GMT -6 hours).
The Official SABCS® News English website (www.bestofsabcsnews.com) will include daily expert video summaries with original presentation slides of the most significant clinical trials presented each day. World-renowned experts such as Drs. Kaklamani, Rugo, and Gradishar among others will present the key takeaways from the major trials from #SABCS20 including:
Additional SABCS® News language versions will be accessible on https://www.bestofsabcs.com/best-of-sabcs-news/:
About Best of SABCS® programs
The San Antonio Breast Cancer Symposium®, now in its 43rd year, is the premier conference for basic, translational, and clinical cancer research professionals. It is well-known for presenting the latest breast cancer data from all over the world.
Best of SABCS® programs offer professionals the opportunity to experience and discuss the most current research and advances in the field of breast cancer with colleagues and key opinion leaders with access to the original presentations and posters.
For information on Best of SABCS® opportunities, please contact Encore Medical Education LLC, the exclusive agent of the SABCS® for the dissemination of Symposium content internationally, at sabcs@encoremeded.com
SOURCE Encore Medical Education
Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…
YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…
Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…
TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…